Return On Invested Capital
-19%
Trailing 12 months · Through 30 Jun 2026
Prior-year balance unavailable; uses current balance.
Assumes a 21% tax rate.
Apimeds Pharmaceuticals US, Inc. financial metrics
Period Q2 2026 · Filed 14 Aug 2026
Key metrics snapshot
Return On Equity
-100%
Trailing 12 months · Through 30 Jun 2026
YoY relative change: +22%
Return On Assets
-84%
Trailing 12 months · Through 30 Jun 2026
YoY relative change: +139%
Operating Margin
0%
Third-party reference; reporting period not verified
Current Ratio
0.51x
Period-end balance · Through 30 Jun 2026
YoY relative change: -96%
Debt-to-equity
0.05x
Period-end balance · Through 30 Jun 2026
NetIncomeLoss YoY
-1468%
Trailing 12 months · Through 30 Jun 2026
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Invested Capital |
-19%
Trailing 12 months · 30 Jun 2026
Prior-year balance unavailable; uses current balance. Assumes a 21% tax rate.
|
|
| Return On Equity |
-100%
Trailing 12 months · 30 Jun 2026
|
+22% |
| Return On Assets |
-84%
Trailing 12 months · 30 Jun 2026
|
+139% |
| Operating Margin |
0%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.51x
Period-end balance · 30 Jun 2026
|
-96% |
| Debt-to-equity |
0.05x
Period-end balance · 30 Jun 2026
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-1468%
Trailing 12 months · 30 Jun 2026
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
15,091,177
Period-end balance · 26 May 2026
|
+30% |
| Common Stock, Shares, Outstanding |
1,509,118
Period-end balance · 30 Jun 2026
|
-88% |
| Common Stock, Value, Issued |
$1,509
Period-end balance · 30 Jun 2026
|
-99% |
| Weighted Average Number of Shares Outstanding, Basic |
1,713,402
Reported period · 30 Jun 2026
|
+65% |
| Weighted Average Number of Shares Outstanding, Diluted |
1,713,402
Reported period · 30 Jun 2026
|
+65% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accrued Liabilities, Current |
$780,000
Period-end balance · 30 Jun 2026
|
|
| Additional Paid in Capital |
$168,436,065
Period-end balance · 30 Jun 2026
|
+887% |
| Assets |
$127,623,697
Period-end balance · 30 Jun 2026
|
+1110% |
| Assets, Current |
$10,678,438
Period-end balance · 30 Jun 2026
|
+3.2% |
| Cash and Cash Equivalents, at Carrying Value |
$278,371
Period-end balance · 30 Jun 2026
|
-97% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$8,278,371
Period-end balance · 30 Jun 2026
|
-5.2% |
| Common Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 30 Jun 2026
|
-90% |
| Common Stock, Shares Authorized |
100,000,000
Period-end balance · 30 Jun 2026
|
0% |
| Common Stock, Shares, Issued |
1,509,118
Period-end balance · 30 Jun 2026
|
-88% |
| Common Stocks, Including Additional Paid in Capital |
$20,311
Period-end balance · 30 Jun 2026
|
|
| Depreciation |
$4,662
Reported period · 30 Jun 2026
|
+1909% |
| Earnings Per Share, Basic |
-11.96
Trailing 12 months · 30 Jun 2026
|
-343% |
| Earnings Per Share, Diluted |
-11.96
Trailing 12 months · 30 Jun 2026
|
-343% |
| General and Administrative Expense |
$24,507,061
Trailing 12 months · 30 Jun 2026
|
+730% |
| Lessee, Operating Lease, Liability, to be Paid |
$172,285
Period-end balance · 30 Jun 2026
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$67,310
Period-end balance · 30 Jun 2026
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$69,330
Period-end balance · 30 Jun 2026
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$10,889
Period-end balance · 30 Jun 2026
|
|
| Liabilities |
$21,175,156
Period-end balance · 30 Jun 2026
|
+2517% |
| Liabilities and Equity |
$127,623,697
Period-end balance · 30 Jun 2026
|
+1110% |
| Liabilities, Current |
$21,073,283
Period-end balance · 30 Jun 2026
|
+2505% |
| Nonoperating Income (Expense) |
$30,820,784
Trailing 12 months · 30 Jun 2026
|
-29292% |
| Operating Income (Loss) |
$27,348,744
Trailing 12 months · 30 Jun 2026
|
-659% |
| Operating Lease, Liability |
$161,396
Period-end balance · 30 Jun 2026
|
|
| Operating Lease, Liability, Current |
$59,523
Period-end balance · 30 Jun 2026
|
|
| Operating Lease, Liability, Noncurrent |
$101,873
Period-end balance · 30 Jun 2026
|
|
| Operating Lease, Right-of-Use Asset |
$156,162
Period-end balance · 30 Jun 2026
|
|
| Operating Lease, Weighted Average Discount Rate, Percent |
0.05
Period-end balance · 30 Jun 2026
|
|
| Other Assets, Current |
$48,501
Period-end balance · 30 Jun 2026
|
|
| Preferred Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 30 Jun 2026
|
-90% |
| Preferred Stock, Shares Authorized |
10,000,000
Period-end balance · 30 Jun 2026
|
0% |
| Preferred Stock, Shares Issued |
747,702
Period-end balance · 30 Jun 2026
|
|
| Preferred Stock, Shares Outstanding |
747,702
Period-end balance · 30 Jun 2026
|
|
| Property, Plant and Equipment, Gross |
$66,727
Period-end balance · 30 Jun 2026
|
|
| Property, Plant and Equipment, Net |
$51,929
Period-end balance · 30 Jun 2026
|
+295% |
| Research and Development Expense |
$959,742
Reported period · 30 Jun 2026
|
+47% |
| Retained Earnings (Accumulated Deficit) |
$65,626,043
Period-end balance · 30 Jun 2026
|
-780% |
| Share-based Payment Arrangement, Expense |
$105,210
Reported period · 30 Jun 2026
|
-45% |
| Stockholders' Equity Attributable to Parent |
$106,448,541
Period-end balance · 30 Jun 2026
|
+993% |
Comparisons, sources and research notes
Sources and sharing
APUS - Apimeds Pharmaceuticals US, Inc. Financial Facts
- Context
- Latest metrics period: Q2 2026
- Latest reported value
- Return On Invested Capital -19%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q2 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q2 2026.
- Most recent SEC facts end date on this page: 30 Jun 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for APUS - Apimeds Pharmaceuticals US, Inc.
Latest financial period: Q2 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
14 Aug 2026
Page type
Company facts
Latest period
Q2 2026
SEC-backed company facts were refreshed from filings filed on 14 Aug 2026.
Benchmark Context
How Return On Invested Capital compares
Return On Invested Capital does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with Apimeds Pharmaceuticals US, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Invested Capital already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q2 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- APUS - Apimeds Pharmaceuticals US, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q2 2026.
- Headline metric: Return On Invested Capital -19%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 30 Jun 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-06-30) highlights Return On Invested Capital -19.4%, Return On Equity -100.1%, and Return On Assets -84.2%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-14885%
fair value gap
Fair value per share
$96.10
Market price
$0.6500
APUS - Local security
PEG ratio
n/a
Enterprise value
$159.94M
Equity value
$164.67M
DCF fair value scenarios
Bear
$72.43
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -11242%
Base
$96.10
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -14885%
Bull
$133.39
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -20621%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Local security market EV / SEC revenue
Revenue is unavailable or not positive
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Ebitda is unavailable or not positive
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
n/a
Local security market cap / SEC revenue
Revenue is unavailable or not positive
P/B
0.0x
Local security market cap / SEC equity
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $10.98M
- Trailing SEC FCF
- Reported FCF
- $10.98M
- Net income
- $58.17M
- EBITDA
- $27.34M
- Cash
- $278.4K
- Debt
- $5M
- Equity
- $106.45M
- Shares
- 1,713,402
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: recent annual free cash flow history is thin
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: earnings per share is not positive
Compare This Company Through SEC-backed Metrics
Use these links to compare APUS - Apimeds Pharmaceuticals US, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: -1468%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
19.6/100
Weak Confidence high
Return On Invested Capital
-19%
Metric score 0.0/100
Return On Equity
-100%
Metric score 0.0/100
Return On Assets
-84%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.51x
- Debt to Equity
- 0.05x
Strengths
Debt-to-equity
Watchpoints
Return On Invested Capital, Return On Equity, and Return On Assets
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first